FDA Compliance Infrastructure
PeptidePilot automatically updates intake forms, contraindication logic, and chart templates the moment the FDA moves a substance — so your clinic never falls behind the compounding calendar.
The Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to formally evaluate these substances for Category 1 inclusion. Whatever they decide, PeptidePilot adapts with them — automatically.
What PeptidePilot does
Patient intake forms that shift based on current FDA substance categories. When BPC-157 moves to Category 1, your intake updates. When it doesn't, your clinic stays protected.
Real-time contraindication logic built into the encounter workflow. Cross-references current medications, lab values, and FDA category status before any peptide is routed to pharmacy.
Direct routing to verified 503A compound pharmacies with active COA tracking and audit logs. Automatic re-routing if a pharmacy cannot fulfill — patient never experiences a gap in care.
Canvas chart templates that pull the substance's current FDA category at write-time. Notes include compliance documentation, COA references, and medical necessity language — audit-ready by default.
What's coming
BPC-157, TB-500, KPV, MOTs-C, CJC-1295, and 7 others exit the "do not compound" list — entering a gray zone neither authorized nor prohibited.
Every peptide clinic that hasn't updated intake forms, charting templates, and pharmacy contracts is operating outside best-practice compliance.
FDA's Pharmacy Compounding Advisory Committee formally evaluates these substances for 503A Bulk List inclusion. The outcome reshapes the entire peptide clinic landscape — for better or worse.
Clinics without adaptive compliance tools face state board exposure, pharmacy liability, and patient safety risk. PeptidePilot is the platform that keeps you ahead of every decision.
Pricing
No per-user fees. No setup fees. No contracts longer than monthly.
PeptidePilot exists because the FDA changes faster than clinics can.